Au, Switzerland

Philipp Spycher

This inventor holds 1 USPTO granted patent and 8 published patent applications. Top assignee: Araris Biotech Ag. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Philipp Spycher: Innovator in Antibody-Drug Conjugates

Introduction

Philipp Spycher is a notable inventor based in Au, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. His innovative work has the potential to enhance therapeutic options in medicine.

Latest Patents

Philipp Spycher holds a patent for "Antibody-drug conjugates through specific linker oligopeptides." This invention relates to a method for generating an antibody-payload conjugate using microbial transglutaminase (MTG). The method involves conjugating a linker to a Gln residue in an antibody, which can improve the efficacy of drug delivery systems.

Career Highlights

Philipp Spycher is associated with Araris Biotech AG, a company focused on advancing biopharmaceuticals. His work in this organization has been pivotal in pushing the boundaries of antibody-drug conjugate technology. He has successfully developed methods that could lead to more effective cancer treatments.

Collaborations

Philipp Spycher collaborates with talented professionals in his field, including Philipp Probst and Isabella Attinger-Toller. These partnerships enhance the research and development efforts at Araris Biotech AG, fostering innovation and progress in biotechnology.

Conclusion

Philipp Spycher's contributions to the field of antibody-drug conjugates exemplify the impact of innovative thinking in biotechnology. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…